Tadvest Limited (NMSE:TAD)

Lumos Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1.93	1.13	0.31	0.27	0.15	0.12
Trading Asset Securities	-	2.06	2.76	3.54	4.92	4.77
Cash & Short-Term Investments	1.93	3.19	3.06	3.81	5.07	4.89
Cash Growth	9685.69%	4.17%	-19.65%	-24.73%	3.62%	9.30%
Accounts Receivable	-	0.01	0	0.03	0.02	0.02
Other Receivables	-	0	-	-	-	-
Receivables	-	2.22	2.95	2.47	6.89	2.43
Prepaid Expenses	-	0.01	0.01	-	-	-
Total Current Assets	6	5.42	6.03	6.29	11.96	7.32
Long-Term Investments	-	76.54	67.82	62.09	54.77	50.24
Total Assets	80.21	82.75	74.63	68.38	66.73	57.57
Accounts Payable	-	-	-	-	-	0.03
Accrued Expenses	0.1	0.19	0.04	0.04	0.03	-
Current Income Taxes Payable	-	0.01	0.01	0.01	-	-
Total Current Liabilities	0.1	0.19	0.05	0.05	0.03	0.03
Total Liabilities	0.1	0.19	0.05	0.05	0.03	0.03
Common Stock	42.88	42.88	42.88	42.88	42.88	42.88
Retained Earnings	37.23	39.68	31.69	25.45	23.81	14.66
Shareholders' Equity	80.11	82.56	74.57	68.33	66.7	57.54
Total Liabilities & Equity	80.21	82.75	74.63	68.38	66.73	57.57
Net Cash (Debt)	1.93	3.19	3.06	3.81	5.07	4.89
Net Cash Growth	9685.69%	4.17%	-19.65%	-24.73%	3.62%	9.30%
Net Cash Per Share	0.04	0.07	0.07	0.09	0.11	0.11
Filing Date Shares Outstanding	44.79	44.79	44.79	44.79	44.79	44.79
Total Common Shares Outstanding	44.79	44.79	44.79	44.79	44.79	44.79
Working Capital	5.9	5.23	5.98	6.24	11.93	7.3
Book Value Per Share	1.79	1.84	1.66	1.53	1.49	1.28
Tangible Book Value	80.11	82.56	74.57	68.33	66.7	57.54
Tangible Book Value Per Share	1.79	1.84	1.66	1.53	1.49	1.28

Source: S&P Global Market Intelligence. Standard template. Financial Sources.